Exonate Taps Olav Hellebø as EXN407 Nears Phase 2b

• July 23, 2026

Does Timing Matter in Gene Therapy for nAMD?

Carl C. Awh, MD, FASRS, discusses 2-year phase 2b PRISM results showing durable outcomes with investigational 4D-150 in patients with recently diagnosed neovascular age-related macular degeneration.

• by Carl C. Awh, MD

• July 15, 2026

• 2 min

The Economics of Home OCT

At ASRS 2026, Sean Berkowitz, MD, MBA, examined the payer costs and physician workload associated with home OCT monitoring for wet AMD.

• by Jim Gallagher, senior managing editor

• July 15, 2026

• 4 min

Drs. Berrocal Reflect on ASRS 2026

ASRS 2026 meeting program chair Audina M. “Nina” Berrocal, MD, FASRS, joins Maria H. Berrocal, MD, to discuss the meeting’s highlights, surgical sessions, and educational approach.

• by Audina M. Berrocal, MD, Maria H. Berrocal, MD

• July 15, 2026

• 3 min